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Clinical Science
Both	atherosclerosis	and	obesity,	an	independent	atherosclerotic	risk	factor,	are	
associated	with	enhanced	systemic	inflammation.	Obesity	is	also	characterised	by	
increased	adipose	tissue	inflammation.	However,	the	molecular	mechanism	
underlying	the	accelerated	atherosclerosis	in	obesity	remains	unclear.	In	obesity,	
activation	of	c‐Jun	N‐terminal	kinase	(JNK)	contributes	to	adipose	tissue	
inflammation.	This	study	investigated	whether	the	suppression	of	fat	inflammation	
through	adipose‐specific	JNK	inactivation	could	protect	against	atherosclerosis	in	
mice.	ApoE‐/‐	mice	were	crossbred	with	transgenic	mice	with	adipose‐specific	
expression	of	a	dominant	negative	form	of	JNK	(dnJNK)	to	generate	apoE‐/‐/dnJNK	
(ADJ)	mice.	High‐fat‐high‐cholesterol	diet‐treated	ADJ	mice	exhibited	significant	
attenuations	of	visceral	fat	and	systemic	inflammation	without	changes	in	lipid	or	
glucose	metabolism,	and	were	protected	against	atherosclerosis,	when	compared	to	
apoE‐/‐	mice.	Lean	apoE‐/‐	mice	that	received	transplantation	of	visceral	fat	from	
obese	wild‐type	donor	mice	for	4	weeks	showed	exacerbated	systemic	inflammation	
and	atherosclerotic	plaque	formation.	Conversely,	apoE‐/‐	recipients	carrying	
visceral	fat	graft	from	obese	dnJNK	donors	were	protected	against	enhanced	
systemic	inflammation	and	atherogenesis.	The	beneficial	effects	of	adipose‐specific	
JNK	inactivation	on	atherogenesis	in	apoE‐/‐	recipients	were	significantly	
compromised	by	continuous	infusion	of	recombinant	adipocyte‐fatty	acid	binding	
protein	(A‐FABP),	previously	shown	to	interact	with	JNK	via	a	positive	feedback	loop	
to	modulate	inflammatory	responses.	Together	these	data	suggested	that	enhanced	
atherosclerosis	in	obesity	can	be	attributed,	at	least	in	part,	to	a	distant	cross‐talk	
between	visceral	fat	and	the	vasculature,	mediated	by	the	release	of	pro‐
inflammatory	cytokines,	such	as	A‐FABP,	from	the	inflamed	visceral	adipose	tissue	
with	JNK	activation. 
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Abstract 
Both atherosclerosis and obesity, an independent atherosclerotic risk factor, are associated with enhanced 
systemic inflammation. Obesity is also characterised by increased adipose tissue inflammation. However, the 
molecular mechanism underlying the accelerated atherosclerosis in obesity remains unclear. In obesity, 
activation of c-Jun N-terminal kinase (JNK) contributes to adipose tissue inflammation. This study 
investigated whether the suppression of fat inflammation through adipose-specific JNK inactivation could 
protect against atherosclerosis in mice. ApoE-/- mice were crossbred with transgenic mice with 
adipose-specific expression of a dominant negative form of JNK (dnJNK) to generate apoE-/-/dnJNK (ADJ) 
mice. High-fat-high-cholesterol diet-treated ADJ mice exhibited significant attenuations of visceral fat and 
systemic inflammation without changes in lipid or glucose metabolism, and were protected against 
atherosclerosis, when compared to apoE-/- mice. Lean apoE-/- mice that received transplantation of visceral 
fat from obese wild-type donor mice for 4 weeks showed exacerbated systemic inflammation and 
atherosclerotic plaque formation. Conversely, apoE-/- recipients carrying visceral fat graft from obese dnJNK 
donors were protected against enhanced systemic inflammation and atherogenesis. The beneficial effects of 
adipose-specific JNK inactivation on atherogenesis in apoE-/- recipients were significantly compromised by 
continuous infusion of recombinant adipocyte-fatty acid binding protein (A-FABP), previously shown to 
interact with JNK via a positive feedback loop to modulate inflammatory responses. Together these data 
suggested that enhanced atherosclerosis in obesity can be attributed, at least in part, to a distant cross-talk 
between visceral fat and the vasculature, mediated by the release of pro-inflammatory cytokines, such as 
A-FABP, from the inflamed visceral adipose tissue with JNK activation. 
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Non-standard Abbreviations and Acronyms 
ADJ – apoE-/-/dnJNK 
A-FABP – adipocyte fatty acid binding protein 
CLS – crown-like structure 
Cox2 – cyclooxygenase 2 
dnJNK – dominant-negative c-Jun N-terminal kinase 
eWAT – epididymal white adipose tissue 
GLUT4 – glucose transporter 4 
IL-1β – interleukin 1β 
IL-6 – interleukin 6 
JNK – c-Jun N-terminal kinase 
LPL – lipoprotein lipase 
MCP-1 – monocyte chemoattractant protein 1  
MMP9 – matrix metalloproteinase 9 
scWAT – subcutaneous white adipose tissue 
sTNFR2 – soluble tumour necrosis factor receptor 2 
TNF-α – tumour necrosis factor α 
VCAM-1 – vascular cell adhesion molecule 1 
 
 
Summary Statement 
The contribution of adipose tissue inflammation, a hallmark of obesity, in atherosclerosis development is 
unclear. Using transgenic and fat transplantation models, this study showed that JNK in adipose tissue 
promotes atherogenesis, in part through actions of A-FABP in the circulation. 
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Introduction 
Atherosclerosis is a chronic inflammatory disease characterised by the development of atheromatous plaques 
at the intimal layer of arteries. Substantial evidence suggested that inflammation is an active participant in 
almost all critical stages of atherogenesis (1), including endothelial activation, foam cell formation (2), 
vascular smooth muscle cell proliferation and migration, extracellular matrix remodelling (3), plaque rupture, 
and thrombus formation (4). In humans, atherosclerosis is associated with elevated systemic levels of 
inflammatory markers, such as C-reactive protein (CRP) (5) and interleukin 6 (6). A causal effect of 
inflammation on atherogenesis was suggested by results from the recent JUPITER trial, where the reduction in 
circulating CRP levels following statin treatment in normolipidaemic individuals correlated with reduced 
cardiovascular event rates (7). Studies in patients with rheumatoid arthritis further suggested that systemic 
inflammation mediates and sustains atherogenesis (8). 
 
Obesity, a strong independent risk factor for cardiovascular diseases (9), is featured by chronic systemic 
inflammation (10). Visceral adipose tissue has been suggested to be the major contributor for this systemic 
inflammation, in view of its greater capacity for the production and secretion of pro-inflammatory cytokines 
into the circulation as compared with subcutaneous depot (11). Clinically, indices of central or abdominal 
obesity show a stronger correlation with cardiovascular mortality compared to body mass index, a measure of 
total obesity (12). In atherogenic apoE-deficient mice (apoE-/-), the subcutaneous transplantation of visceral 
adipose tissue with local post-traumatic inflammation from lean mice, was associated with elevated systemic 
inflammation and accelerated atherogenesis (13), suggesting that inflamed visceral adipose tissue can promote 
atherogenesis by driving systemic inflammation. However, the underlying molecular pathways linking 
adipose tissue inflammation with atherosclerosis in obesity remain to be elucidated. 
 
The c-Jun N-terminal kinase (JNK) is an important mediator of inflammation (14). JNK activation is observed 
in the liver, muscle and adipose tissue of mice with genetic or diet-induced obesity, and has been implicated in 
promoting hepatic and peripheral insulin resistance (15). Interestingly, the selective inactivation of JNK in 
adipose tissue alone in mice with diet-induced obesity led to, not only improved insulin sensitivity, but also 
alleviated systemic inflammation (16). Therefore, JNK may represent a molecular link between adipose tissue 
inflammation and atherogenesis in obesity. In this study, we employed a transgenic mouse model in which 
JNK is selectively inactivated in adipose tissue by overexpression of a dominant negative form of JNK, under 
the control of the aP2 promoter (16), to investigate the effect of amelioration of JNK-mediated adipose tissue 
inflammation on atherogenesis in mice on high-fat-high-cholesterol diet, and explore the possible mechanisms 
involved. 
 
 
Methods 
Animals 
ApoE-/- mice and dominant negative JNK (dnJNK) transgenic mice (16), both in C57BL/6 background, were 
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crossbred to generate apoE-/-/dnJNK (ADJ) mice. ApoE-/- and ADJ mice were fed with a 
high-fat-high-cholesterol (HFHC) diet (40 kcal% fat, 0.21% cholesterol; D12079B; Research Diets, USA) for 
10 weeks. For fat transplantation studies, donor mice were fed with a HFHC diet for 12 weeks before being 
sacrificed, while recipient mice were maintained on a standard chow diet (13 kcal% fat; 5053; LabDiet, USA) 
throughout the experiment. Recipient mice underwent fat transplantation at the age of 10 weeks. 
For intra-peritoneal glucose tolerance test (IP-GTT), mice were fasted for 16 hours, followed by 
intra-peritoneal injection of glucose at a dosage of 2 g/kg. Blood glucose level was measured at specified time 
points using a glucometer (F. Hoffman-La Roche Ltd, Switzerland). Body composition and fat mass were 
determined by nuclear magnetic resonance method (Minispec LF90, Bruker, Germany). Animals were 
maintained on 12-hour light-dark cycles at controlled temperature (23±1˚C). Diet and water were provided ad 
libitum. 
All animal procedures were approved by the Committee of the Use of Live Animals in Teaching and Research 
at the University of Hong Kong. 
 
Adipose Tissue Transplantation 
Adipose tissue transplantation was performed as previously described (13). Briefly, recipient mice were 
anaesthetised by intra-peritoneal injection of Hypnorm and Dormicum solution (fentanyl, 0.4 mg/kg; 
fluanisone, 12.5 mg/kg; midazolam, 6.25 mg/kg). After hair removal, the skin on the dorsal region was 
disinfected with iodine solution. Epididymal white adipose tissue (eWAT) of a total of 900 mg was harvested 
from donor mice, weighed, and subcutaneously transplanted into 4 dorsal incision sites in recipient mice. 
Incisions were closed up using 5-0 nylon monofilament (Ethicon, USA). For sham operation, recipients 
received identical treatment except that no adipose tissue was transplanted. Satisfactory survival of fat graft 
was ensured by histological analysis. 
 
Atherosclerosis Assessment 
Atherosclerotic plaque was examined in aortic tree and root region. Upon sacrifice, mice were subjected to 
transcardial perfusion with phosphate buffered saline (PBS) at a rate of 1 ml/min using a cannula inserted into 
the left ventricle. The aortic tree was meticulously dissected, preserving the aortic arch and arterial branches 
including brachiocephalic, subclavian, carotid and occipital arteries. Perivascular adipose tissue and 
connective tissue were removed from the aortic tree. Dissected aortic tree was fixed in 4% paraformaldehyde 
in PBS at 4˚C overnight, followed by rinsing in distilled water. After en face staining with 0.3% Oil Red O 
(Sigma-Aldrich, USA) for 20 minutes, the aortic tree was then washed in 60% isopropanol and laid flat on 
black wax for imaging. The area showing positive Oil Red O staining was measured using NIH ImageJ 
Software, and expressed as a percentage of the total area examined. 
For aortic root analysis, the heart was harvested and cut into two halves along the axial plane using a razor 
blade. The heart was embedded in Optimal Cutting Temperature (OCT) compound (Sakura, USA) with the cut 
side facing down and immediately frozen in dry ice. Approximately 48 sections of 10 μm thick spanning the 
aortic root were collected. Cryosections were fixed in 4% paraformaldehyde for 5 minutes and washed with 
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distilled water. After being stained with 0.3% Oil Red O for 20 minutes, sections were washed with 60% 
isopropanol, and finally mounted with coverslips using aqueous mounting medium (Dako, Denmark). Images 
were captured using an Olympus BX41 microscope. The area showing positive Oil Red O staining was 
expressed as a percentage of the aortic root area. Comparison was made between sections collected at the 
same positions along the aortic root. 
 
Production and Infusion of Recombinant Mouse Adipocyte Fatty Acid Binding Protein (A-FABP) 
Recombinant mouse A-FABP was produced as previously described (17). Briefly, mouse A-FABP gene was 
cloned into pPROEX-HTb His-tag expression vector (Invitrogen, USA) and transformed into Escherichia coli 
BL21 competent cells. Expression of A-FABP was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG) 
treatment (0.25 mM) at 37 ˚C for 4 hours. Bacterial lysate was applied to Ni-NTA affinity column (Qiagen, 
Netherland), followed by treatment with washing buffer (300 mM sodium chloride, 50 mM sodium 
dihydrogen phosphate, 10 mM imidazole, pH 8.0). The bound His-tagged A-FABP protein was eluted with 
100 mmol/ml imidazole, dialysed against PBS, and cleared of endotoxin (<0.02 EU/μg) (Hycult Biotech, USA) 
through endotoxin removing column (Thermo Scientific, USA). The purity of A-FABP was confirmed by 
SDS-PAGE Coomassie Blue staining. A total of 440 μg A-FABP was infused using osmotic pump (Alzet, 
USA) at a rate of 0.44 μg/hr over 4 weeks. Osmotic pump was implanted subcutaneously at mid-scapular 
region. 
 
Statistical Analysis 
Data were expressed as mean ± SEM. Statistical significance was determined by Student’s t test, or by 
One-Way ANOVA followed by Tukey post-hoc test. Correlations were calculated using Pearson correlation 
coefficient (r). In all comparisons, p values less than 0.05 were taken as statistically significant. All statistical 
analyses were performed using Graphpad Prism 5.0. 
 
 
Results 
Adipose-specific JNK Inactivation Significantly Suppressed Inflammatory Response in Visceral Adipose 
Tissue in ApoE-/- Mice 
In the ADJ mice, the mRNA and protein product of the dnJNK transgene (Supplemental Figure 1A) were 
detected in the adipose tissues, including epididymal (eWAT) and subcutaneous white adipose tissue (scWAT), 
but not in other metabolically active organs including the brain, liver and skeletal muscle (Supplemental 
Figure 1B and 1C). Neither the dnJNK mRNA or protein was found in tissues from the apoE-/- 
controls. Data on the protein expression of endogenous JNK and dominant negative JNK are 
presented in Supplemental Figure 1D. The protein level of dnJNK was more than 5-fold higher than that of 
endogenous JNK1 in the adipose tissues of the ADJ mice (Supplemental Figure 1D; right panel), where it 
significantly suppressed JNK activity by up to a mean of 73.2±4.08% and 78.4±4.52% in eWAT and 
scWAT respectively (n=4), as determined by the phosphorylation of c-Jun, a well-established downstream 
6 
 
target of JNK (Supplemental Figure 1E). A weak expression of dnJNK was also observed in the spleen of the 
ADJ mice (Supplemental Figure 1B and 1C), perhaps due to the high abundance of macrophages which also 
express the aP2 gene (18, 19). After 10 weeks of HFHC diet treatment (Figure 1A), the inflammatory response 
in eWAT from ADJ mice was reduced compared to apoE-/- littermates (Figure 1B), with significant reduction 
in the expression of the JNK-targeted proinflammatory genes including MCP-1 (p<0.05), TNF-α (p<0.05), 
A-FABP (p<0.01), and cyclooxygenase 2 (Cox2; p<0.05), and a trend of lower levels of IL-6 and IL-1β. There 
was less macrophage infiltration in eWAT from ADJ, as evidenced by decreased number of crown-like 
structure (CLS) (Figure 1C and 1D) and significantly lower mRNA levels of macrophage cell surface markers 
F4/80 and CD68 (Figure 1E). Since MCP-1, TNF-α and A-FABP were the 3 most down-regulated 
pro-inflammatory cytokines, we further determined their secretion levels from eWAT. There was a significant 
drop in the concentration of MCP-1 (p<0.05) and A-FABP (p<0.01) in the eWAT explant medium from ADJ 
mice (Figure 1F and 1H respectively), while the drop in TNF-α concentration approached statistical 
significance (p=0.053; Figure 1G). On the other hand, the mRNA expression (Figure 1B) and explant levels of 
adiponectin (Figure 1I), an anti-inflammatory adipokine, were not significantly different between apoE-/- and 
ADJ mice. Moreover, there was no significant difference between scWAT from apoE-/- and ADJ mice in terms 
of the expression and secretion of cytokines, and macrophage infiltration (Supplemental Figure 2). 
 
ADJ Mice Showed Significantly Alleviated Atherosclerosis 
We next investigated whether a dampened inflammatory response in the visceral adipose depot in atherogenic 
mice has any effect on atherosclerosis development. Oil Red O en face staining showed a marked reduction in 
atherosclerotic plaque formation along the aortic tree in HFHC-fed ADJ mice compared to HFHC-fed apoE-/- 
mice (p<0.001; Figure 2A), notably at the aortic arch, brachiocephalic artery, external common artery and 
occipital artery, as well as at the aortic root of ADJ mice (p<0.01; Figure 2B). There was less macrophage 
accumulation as reflected by MOMA-2 staining, and fewer vascular smooth muscle cells as reflected by 
α-actin staining (p<0.001; Figure 2C and 2D respectively). No co-staining in the same cells for MOMA-2 and 
α-actin within the plaques was observed (Supplemental Figure 4A). Collagen content in the atherosclerotic 
plaques at the aortic root in the ADJ mice was also lower compared to apoE-/- mice (p<0.001; Figure 2E). In 
line with these histology results, the gene expression of MCP-1, TNF-α, vascular cell adhesion molecule-1 
(VCAM-1), smooth muscle α-actin, and macrophage markers F4/80 and CD68 were significantly 
down-regulated in aorta from ADJ mice (Figure 2F). Basic metabolic parameters including body weight, fat 
mass, glucose tolerance and lipid profile were not different between apoE-/- and ADJ mice, which were 
consistent with the lack of changes in the expression levels of target genes of peroxisome 
proliferator-activated receptor (PPAR) α and δ in adipose tissue, including lipoprotein lipase (LPL), CD36 and 
glucose transporter 4 (GLUT4) (Supplemental Figure 3). 
 
Alleviation in Visceral Adipose Depot Inflammation and Atherosclerosis in ADJ Mice were Associated 
with Decreased Systemic Inflammation 
As our results suggested that the difference in atherosclerotic plaque formation was not due to changes in 
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glucose or lipid metabolism, we next investigated whether apoE-/- and ADJ mice differed in systemic 
inflammatory status, a hallmark of both obesity and atherosclerosis. Consistent with the above gene 
expression and explant culture results in eWAT, the circulating levels of MCP-1, soluble tumour necrosis 
factor receptor 2 (sTNFR2, a surrogate circulating marker for TNF-α activity in obesity (20, 21)) and A-FABP 
were significantly decreased by 47% (p<0.05), 31% (p<0.05) and 54 % (p<0.001), respectively in ADJ mice 
(Figure 3A to 3C), whereas the circulating levels of adiponectin was not significantly different between  
apoE-/- and ADJ mice (Figure 3D). 
 
Obesity-induced JNK-mediated Inflammation in eWAT Graft Accelerated Atherogenesis in Recipient 
ApoE-/- Mice 
As the aP2 promoter may have led to the expression of dnJNK locally at the vasculature, such as in 
perivascular adipocytes, macrophages (18, 19) and even endothelial cells (22, 23), the following 
experiment was carried out to demonstrate, more confirmatively, that accelerated atherosclerosis in obesity 
results from a long-distance communication between the inflamed visceral adipose tissue and the vasculature. 
We transplanted eWAT isolated from obese donor mice into apoE-/- recipients. This approach ensured that the 
effects of adipose-selective JNK inactivation were restricted only to the transplanted fat tissue in the recipient. 
Briefly, we performed sham operation, or transplanted eWAT from either wildtype (WT) or dnJNK mice 
which had both been fed a HFHC diet for 12 weeks to maximise obesity-induced adipose tissue inflammation, 
into lean apoE-/- recipient mice subcutaneously (0.9 g fat graft per recipient). Thereby, 3 transplantation 
groups were generated: (sham)apoE-/-, (WT)apoE-/- and (dnJNK)apoE-/-, respectively (Figure 4A). We 
previously showed that adipose tissue inflammation in obese dnJNK mice was ameliorated compared to that 
from obese WT mice (16). Notably, after 4 weeks of transplantation, the fat graft from dnJNK donors 
remained less inflamed compared to that from WT donors, as evidenced by significantly attenuated expression 
of pro-inflammatory cytokines (Figure 4B), macrophage infiltration (Figure 4C to 4E) and cytokine secretion 
(Figure 4F to 4H). The reduction in graft mRNA level, relative to that of graft from WT donors, was 81.6%, 
45.9% and 83.4% for MCP-1, TNF-α and A-FABP respectively, while the drop in cytokine level in graft 
explant medium, compared to that of graft from WT donors, was 69.4%, 38% and 61.5% for MCP-1, TNF-α 
and A-FABP respectively. Thus, the changes in gene expression and protein secretion of MCP-1, TNF-α and 
A-FABP again stood out from other JNK-targeted pro-inflammatory genes with the greatest magnitude of 
down-regulation in response to JNK inactivation (Figure 4B). Despite satisfactory graft survival 
(Supplemental Figure 4B), there was a slight reduction in the weight of all fat grafts from both WT and 
dnJNK donors by 4 weeks after transplantation (0.7920±0.1518 g and 0.7700±0.06129 g respectively; 
p=0.874). This reduction was likely contributed by a switch from HFHC diet in donor mice to standard chow 
diet in recipient mice. There was no difference in the inflammatory states of endogenous scWAT and eWAT 
from all 3 transplantation groups (Supplemental Figure 5). 
 
The dorsal-subcutaneous transplantation of eWAT from obese WT donors for just 4 weeks significantly 
exacerbated atherosclerotic plaque formation in the aortic tree and root of (WT)apoE-/- mice, compared to 
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(sham)apoE-/- mice (p<0.01; Figure 5A and 5B respectively). Since these recipient mice were relatively 
young and fed with standard chow diet, the plaques localised mostly to the brachiocephalic artery only. The 
aortic root from (WT)apoE-/- mice exhibited significantly elevated macrophage infiltration (p<0.01; Figure 
5C), vascular smooth muscle cell number (p<0.05; Figure 5D), and increased collagen content (p<0.05; Figure 
5E), compared to (sham)apoE-/- mice. Conversely, these detrimental effects were significantly blunted in 
(dnJNK)apoE-/- mice (Figure 5A to 5E). The mRNA levels of MCP-1, TNF-α, VCAM-1, α-actin, F4/80 and 
CD68 in aorta showed a similar trend and further supported the histological analyses (Figure 5F). (Our 
preliminary data suggested that largely comparable changes in atherosclerotic plaque formation in the 
recipients could also be observed if apoE-/- and ADJ mice were used instead as the donors [Supplementary 
Figure 6]). 
 
(WT)apoE-/- Mice Displayed Augmented Systemic Inflammation, which was Absent in (DnJNK)apoE-/- 
Mice 
Body weight, glucose and lipid metabolism in recipient mice did not show any significant changes among all 
3 groups throughout the transplantation period (Supplemental Figure 7). On the contrary, the degree of 
systemic inflammation in recipient mice varied accordingly in response to the differential inflammation in 
eWAT graft, and was accompanied by a similar pattern in the extent of plaque development. The circulating 
levels of MCP-1, sTNFR2 and A-FABP were elevated by 1.9- (p<0.05; Fig. 6A), 1.4- (p<0.05; Figure 6B) and 
3.2-fold (p<0.01; Figure 6C) respectively in (WT)apoE-/- mice compared to the (sham)apoE-/- group. In 
(dnJNK)apoE-/- group, the circulating levels of sTNFR2 and A-FABP were significantly reduced by 25.4% 
and 38.6% respectively, relative to those in (WT)apoE-/- mice (p<0.05; Figure 6B and 6C), and were 
comparable to those in (sham)apoE-/- group; whereas the drop in MCP-1 level in the (dnJNK)apoE-/- group 
compared to (WT)apoE-/- did not reach statistical significance (Figure 6A). 
 
Infusion of Recombinant A-FABP Compromised the Beneficial Effects Exerted by Adipose-specific JNK 
Inactivation on Atherosclerosis Development in (DnJNK)apoE-/- Mice 
We postulated that the marked elevation in circulating levels of pro-inflammatory cytokines originating from 
local JNK-mediated fat inflammation in the eWAT graft was sufficient to promote atherogenesis at the 
vasculature. We tested our hypothesis by studying the role of A-FABP as it was previously shown to be one of 
the important players in JNK-mediated feed-forward inflammatory response (24), and even among the 3 
pro-inflammatory cytokines most prominently down-regulated by JNK inactivation in this study, A-FABP 
expression level showed the most consistent and most significant changes locally and systemically in recipient 
(dnJNK)apoE-/- mice, as described in the preceding sections and Fig 4B, 4F-H and 6A-C. We found that the 
levels of A-FABP in the explant culture medium of eWAT graft, studied 4 weeks after transplantation, 
positively correlated with the circulating levels of A-FABP (Figure 7A), and both of them showed significant 
correlation with the plaque size at the aortic root (Figure 7B and 7C), in accordance with our hypothesis. 
Consistently, A-FABP secreted by eWAT in apoE-/- and ADJ mice also correlated positively with the A-FABP 
levels in serum (Figure 7D) and plaque development (Figure 7E and 7F). 
9 
 
 
To further test our hypothesis, another round of eWAT transplantation was performed in combination with the 
infusion of PBS, or recombinant mouse A-FABP. Four groups of recipient mice were involved: 
(sham/PBS)apoE-/-, (WT/PBS)apoE-/-, (dnJNK/PBS)apoE-/- and (dnJNK/A-FABP)apoE-/- (Figure 8A). 
When infused with recombinant A-FABP, the circulating level of A-FABP in (dnJNK/A-FABP)apoE-/- mice 
(green), which received eWAT graft expressing dnJNK, returned to levels similar to those observed in 
(WT/PBS)apoE-/- mice (blue; Figure 8B). This restitution of circulating A-FABP markedly augmented 
atherosclerosis development in (dnJNK/A-FABP)apoE-/- mice. The extent of plaque formation in these 
recipient mice increased significantly compared to (dnJNK/PBS)apoE-/-, and reverted back to that comparable 
to (WT/PBS)apoE-/- recipients carrying an eWAT graft with functional JNK, as evidenced by both 
histological results (Figure 8C to 8F) and gene expression analyses (Figure 8G). The infusion of recombinant 
A-FABP also led to a significant increase in the circulating level of sTNFR2 (p<0.05), and a trend for 
increased MCP-1, in the (dnJNK/A-FABP)apoE-/- group, compared to the (dnJNK/PBS)apoE-/- group 
(Supplemental Figure 8), suggesting a self-perpetuating inflammatory response. 
 
 
Discussion 
Obesity is strongly associated with increased cardiovascular risks and mortality (12). In obesity, the adipose 
tissue exhibits macrophage infiltration and secretes into the circulation an increased amount of 
pro-inflammatory cytokines, which have been suggested to be detrimental to cardiovascular function and 
health (25). However, the molecular origin of this distant cross-talk between adipose tissue and the 
vasculature remain unclear. In this study, we have provided direct evidence that JNK in the visceral adipose 
tissue acts as a link between local adipose tissue inflammation and atherogenesis, and that selective 
inactivation of JNK in visceral adipose tissue effectively alleviates atherosclerosis in atherogenic apoE-/- 
mice. 
 
JNK is a member of the mitogen-activated protein kinase (MAPK) family (26). It responds to non-esterified 
fatty acid or pro-inflammatory cytokine stimulation by phosphorylating downstream transcription factors, 
including c-Jun and junB (26), which in turn mediate the production of pro-inflammatory cytokines to further 
amplify the inflammatory response (26). In the current study, the double mutant ADJ mice, which were 
apoE-/- mice with adipose tissue-specific JNK inactivation, showed significantly ameliorated inflammation in 
eWAT, but not scWAT, when compared to their apoE-/- littermates. Furthermore, eWAT generally had more 
macrophage infiltration and secreted higher levels of pro-inflammatory cytokines than scWAT in both apoE-/- 
and ADJ mice. Together with the concomitant reduction in the levels of circulating pro-inflammatory 
cytokines in ADJ mice, these results have provided convincing evidence that visceral rather than subcutaneous 
adipose tissue is the predominant contributor to systemic inflammation in obesity.  
 
The effects of local adipose tissue inflammation on atherogenesis were previously studied in mice receiving 
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subcutaneous transplantation of eWAT (13). The transplantation of eWAT from lean apoE-/- donors into lean 
apoE-/- recipients for 10 weeks resulted in local inflammation in the fat graft and accelerated atherogenesis 
(13). This inflammation in the lean fat graft was suggested to originate from adipocyte death caused by the 
surgical procedures (13). which was previously reported to drive macrophage infiltration (27). The authors 
concluded that the elevated circulating MCP-1 level in recipient mice was responsible for the exacerbated 
plaque development (13), since MCP-1 overexpression was previously shown to accelerate atherogenesis in 
apoE-/- mice (28). Conversely, MCP-1 deficiency protected against atherosclerosis (29). In contrast to eWAT 
transplantation, the transplantation of lean scWAT into lean apoE-/- recipients also led to comparable local 
inflammation in the graft, but did not show increased serum levels of MCP-1 nor accelerated atherogenesis 
(13). This implied that the pro-atherogenic effects of eWAT transplantation were due to eWAT-specific 
cytokine secretion profile, even in a lean state, rather than the general surgery-induced inflammation, which 
was also observed in the scWAT transplantation group (13). However, the injury-induced inflammation in 
transplanted, lean adipose tissue may not fully reflect the physiological inflammatory state observed in obesity. 
Furthermore, the molecular origin for the selective release of MCP-1 only by visceral adipose tissue was not 
further explored. 
 
In our study, we adopted and modified the eWAT transplantation experiments performed by Öhman et al (13) 
to generate a truly localised, obesity-induced adipose tissue inflammation in apoE-/- mice. In contrast to using 
lean apoE-/- mice as donors, we used diet-induced obese WT or dnJNK mice, which represented a model 
more reflective of the enhanced adipose tissue inflammation in obesity. In addition, we showed that the 
suppression of JNK-mediated inflammation in eWAT graft from obese dnJNK mice and the subsequent 
reduction in systemic inflammation protected against atherosclerosis development in the recipient apoE-/- 
mice, relative to recipients of eWAT graft from obese WT mice. Notably, there was not only a significant 
reduction in the size of atherosclerotic plaque in the apoE-/- mice, but also in macrophage accumulation, 
smooth muscle cell number, as well as collagen content within the plaque area, suggesting that systemic 
inflammation originating from the inflamed visceral fat graft could promote all major processes in 
atherogenesis. Importantly, these findings again highlighted the pathological relevance of visceral adipose 
tissue in cardiometabolic diseases, and provided further mechanistic insight into the strong association 
between abdominal obesity and cardiovascular mortality (12). 
 
It was initially surprising when the ADJ mice did not exhibit improved metabolism compared to apoE-/- 
littermates. This may be a consequence of the altered metabolism in apoE-/- mice. Both diet-induced (30) and 
genetically obese mice (31) with apoE deficiency were reported to be more resistant to obesity and glucose 
intolerance compared to those without, while mice with human apoE3 knock-in were more susceptible to 
dysregulation in glucose metabolism (32). Despite the lack of impaired glucose metabolism in HFHC 
diet-treated apoE-/- mice, the increased inflammation and oxidative stress in adipose tissue were nevertheless 
retained (30), presumably due to the lack of anti-inflammatory and anti-oxidative actions of apoE (33). The 
inhibitory effects of adipose-specific expression of dnJNK on adipose tissue inflammation could therefore be 
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conferred in ADJ mice, making it a valid mouse model for our study. Collectively, the alleviation of 
atherosclerosis in ADJ mice can be attributed to the reduction in JNK-mediated visceral adipose tissue and 
systemic inflammation, but not a change in glucose or lipid metabolism. 
 
Several studies have reported aP2 promoter activity in macrophages (18, 19) and vascular endothelial cells (22, 
23). The possible expression of dnJNK and hence JNK inactivation in these cells might be a confounding 
factor in investigating the effects of adipose tissue-derived dnJNK on atherosclerosis in our ADJ mice studies. 
The fat transplantation strategy in our current study was designed to exclude this possibility. Compared to the 
ADJ transgenic mouse model, the eWAT transplantation model displayed an even higher adipose-specificity 
for the JNK inactivation, as any differences in atherogenesis in the recipient mice would be caused by JNK 
inactivation only in the transplanted eWAT graft, but not in local tissues, including perivascular fat, at the 
vasculature. Accelerated atherogenesis could be observed in recipient mice carrying locally inflamed WT 
eWAT grafts with functional JNK as early as 4 weeks after transplantation, likely due to the much exacerbated 
inflammatory state in the eWAT graft after 12 weeks of HFHC diet treatment. Accelerated atherogenesis was 
not, however, seen in mice that received dnJNK eWAT grafts with inactive JNK. Of note, the obese and 
inflammatory phenotypes of the eWAT grafts from WT and dnJNK donors slowly disappeared when 
transplanted for a longer period because the recipients were kept on standard chow, in order to minimise any 
phenotypic variation in endogenous adipose tissue. Therefore, a longer transplantation period was not 
desirable for our study. Since the eWAT graft was transplanted into recipient mice as an intact fat pad, its 
contribution to the systemic inflammation was inspected at a whole-tissue level, and the relative importance of 
the adipocytes, macrophages and stromal vascular fraction in this aspect was not further assessed. 
 
Our ELISA results have pointed to at least several possible candidates relaying the distant cross-talk between 
local JNK-mediated adipose tissue inflammation and atherosclerosis, including MCP-1, sTNFR2 and A-FABP. 
Among these, A-FABP has been frequently implicated in human cardiovascular diseases (34). In clinical 
studies conducted by us and others, A-FABP was associated with carotid atherosclerosis (35) and 
macrovascular complications (36), and was predictive of future cardiovascular events (37, 38). In mice, 
genetic deficiency or pharmacological inhibition of A-FABP suppressed atherosclerosis development (39, 40). 
In vitro mechanistic studies showed that A-FABP could directly trigger endothelial dysfunction (41), induce 
foam cell formation through accelerated cholesterol ester accumulation (18), and mediate smooth muscle cell 
proliferation and migration through an ERK-dependent pathway (42). We previously demonstrated that 
A-FABP formed a positive feedback loop with JNK in macrophages to mediate lipopolysaccharide 
(LPS)-mediated inflammation (24), resulting in intensified expression of pro-inflammatory cytokines 
including MCP-1 and TNF-α (24). Based on these findings, we speculated A-FABP to be a key player in the 
adipose-vascular cross-talk. Indeed, the ‘replenishment’ in circulating A-FABP per se in apoE-/- recipient of 
eWAT graft from obese dnJNK mice was able to significantly compromise the beneficial effects on the 
vasculature conferred by adipose-specific JNK inactivation, and reproduced the accelerated atherogenesis 
observed in apoE-/- recipients of eWAT graft from WT obese mice. Notably, the infusion of A-FABP was 
12 
 
accompanied by a significant increase in circulating level of sTNFR2, and a trend for an increase in MCP-1, 
suggesting that elevated circulating A-FABP alone was sufficient to amplify and sustain the systemic 
inflammation. This was probably achieved through the JNK/A-FABP positive feedback loop (24) in 
endogenous tissues such as host macrophages and endothelium at the vasculature. Nevertheless, the role of 
other pro-inflammatory cytokines, including MCP-1 and TNF-α, cannot be excluded, as they have also been 
shown to be downstream of the JNK signalling cascade (24). 
 
This study has several limitations. First, our results were obtained only from mouse models. Further studies in 
larger animals are required before these findings can be translated into clinical use. Second, the role of JNK 
activation in perivascular adipose tissue (pVAT) which had been shown to promote atherogenesis in fat 
transplantation studies in mice (43), was not investigated in this study. 
 
In summary, this study provides direct evidence for an underlying molecular link between obesity and 
atherosclerosis (Supplemental Figure 9). First, inflammatory response exported by obese adipose tissue is a 
major driver of atherogenesis. Second, the suppression of local JNK-mediated adipose tissue inflammation in 
the periphery effectively alleviates atherosclerosis development. Third, A-FABP is a major mediator for the 
distant cross-talk between JNK-mediated adipose tissue inflammation and atherogenesis. Therefore, 
pharmacological suppression of A-FABP activity in adipose tissue and in the circulation represents a potential 
therapeutic and/or preventive approach for obesity-related cardiovascular diseases. In this regard, it is worth 
noting that a decrease in circulating levels of A-FABP has been observed following weight reduction in obese 
subjects (44), and the clinical use of statins (45) and dipeptidyl peptidase-4 (DPP4) inhibitors (46) for 
hypercholesterolaemia and diabetes, respectively. 
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source of systemic inflammation which accelerates atherosclerosis in obesity. 
 We demonstrated a distant cross-talk between the visceral adipose tissue and the vasculature, mediated 
by pro-inflammatory cytokines produced from the inflamed visceral fat. The infusion of A-FABP, a 
pro-inflammatory cytokine which forms a positive feedback loop with JNK in inflammatory response, 
could compromise the beneficial effects of adipose-specific JNK inactivation on atherosclerosis. Taken 
together with published data that high circulating A-FABP levels predicted atherosclerotic diseases in 
humans, these data suggest that life-style and pharmacological measures which reduce A-FABP 
expression in visceral adipose tissue can potentially protect against atherosclerotic diseases. 
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Figure 1. Adipose-specific JNK inactivation significantly suppressed inflammatory response in visceral adipose 
depot. A, HFHC diet treatment in apoE-/- and ADJ mice. B, mRNA expression levels of MCP-1, TNF-α, A-
FABP, Cox2, IL-6, IL-1β,  MMP9 and adiponectin normalised with GAPDH in eWAT. C, Representative images 
of crown-like structures (CLS) stained with rat anti-F4/80 monoclonal IgG (red) and DAPI (blue) in eWAT. D, 
Quantification of number of CLS in eWAT.  E, mRNA expression levels of F4/80 and CD68 normalised with 
GAPDH in eWAT. F-I, Concentrations of MCP-1, TNF-α, A-FABP and adiponectin respectively in eWAT 
explant medium. *P < 0.05, **P < 0.01 versus apoE-/- littermates (n=10-11). 
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Figure 2. ADJ mice were protected against atherosclerosis development. A, Representative en face views of aortic tree 
stained with Oil Red O. B, Representative images of aortic root stained with Oil Red O. C-D, Representative images of 
aortic root stained with DAPI (blue), and rat anti-MOMA-2 monoclonal IgG (red) and mouse anti-α-actin monoclonal 
IgG (green) respectively. E, Representative images of aortic root stained with Masson’s trichrome. F, mRNA 
expression levels of MCP-1, TNF-α, VCAM-1, α-actin, F4/80 and CD68 normalised with GAPDH in aorta. *P < 0.05, 
**P < 0.01, ***P < 0.001 versus apoE-/- littermates (n=10-11). 
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Figure 3. Systemic inflammation was significantly reduced in ADJ mice. A-D, Circulating levels of MCP-1, 
sTNFR2, A-FABP and adiponectin respectively in apoE-/- and ADJ mice. *P < 0.05, *** P < 0.001 versus apoE-
/- littermates (n=10-11). 
D 
ApoE-/- ApoE-/- 
(WT)apoE-/- (Sham)apoE-/- 
WT 
ApoE-/- 
(DnJNK)apoE-/- 
DnJNK 
Obese Donors
12 wk HFHC diet 
eWAT 
Transplantation 
(4 week) 
Lean ApoE-/-
Recipients
10 wk standard chow diet 
A 
F 
C 
H 
B 
D 
(WT)apoE-/- (DnJNK)apoE-/- 
100 μm 
Figure 4. The eWAT graft from dnJNK donors remained less inflamed than that from WT donors after 4 weeks 
of transplantation into recipient apoE-/- mice. A, Overview of eWAT transplantation experiments. B, mRNA 
expression levels of MCP-1, TNF-α, A-FABP, Cox2, IL-6, IL-1β, MMP9 and adiponectin normalised with 
GAPDH in eWAT graft from recipient mice. C, Representative images of CLS in eWAT graft stained with rat 
anti-F4/80 monoclonal IgG (red) and DAPI (blue). D, Quantification of number of CLS in eWAT graft. E, 
mRNA expression levels of F4/80 and CD68 normalised with GAPDH in eWAT graft from recipient mice. F-H, 
Concentrations of MCP-1, TNF-α and A-FABP respectively in eWAT graft explant medium. *P < 0.05, ** P < 
0.01 versus (WT)apoE-/- mice (n=9-12). 
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Figure 5. Effects of eWAT transplantation on atherosclerosis development. Lean recipient apoE-/- mice received either 
sham operation, or eWAT graft from WT or dnJNK donor mice for 4 weeks. A, Representative en face view of aortic 
tree stained with Oil Red O. B, Representative images of aortic root stained with Oil Red O. C-D, Representative 
images of aortic root stained with DAPI (blue), and rat anti-MOMA-2 monoclonal IgG (red) and mouse anti-α-actin 
monoclonal IgG (green) respectively. E, Representative images of aortic root stained with Masson’s trichrome. F, 
mRNA expression levels of MCP-1, TNF-α, VCAM-1, α-actin, F4/80 and CD68 normalised with GAPDH in aorta. *P 
< 0.05, **P < 0.01 (n=9-12). 
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Figure 6. Effects of eWAT transplantation on systemic inflammation. A-C, Circulating levels of MCP-1, sTNFR2 
and A-FABP respectively. *P < 0.05, ** P < 0.01 (n=9-12). 
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Figure 7. Correlations between A-FABP levels secreted by adipose tissue and in the circulation, and 
atherosclerotic plaque development in apoE-/- mice with eWAT transplantation (A-C), and in apoE-/- and ADJ 
mice (D-F). A, A-FABP level in explant culture medium of eWAT graft and serum A-FABP level. B, A-FABP 
level in explant culture medium of eWAT graft and plaque size at the aortic root. C, Serum A-FABP level and 
plaque size at the aortic root. D, A-FABP level in explant culture medium of eWAT and serum A-FABP level. E, 
A-FABP level in explant culture medium of eWAT and plaque size at the aortic root. F, Serum A-FABP level and 
plaque size at the aortic root. 
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Figure 8. Effects of A-FABP infusion on atherosclerosis development in recipient apoE-/- mice. A, Overview of A-
FABP infusion and transplantation experiments. B, Circulating levels of A-FABP in recipient mice after 0, 2 and 4 
weeks (wk) of transplantation. #P < 0.05 versus (WT/PBS)apoE-/- mice. C, Representative images of aortic root stained 
with Oil Red O. D-E, Representative images of aortic root stained with DAPI (blue), and rat anti-MOMA-2 monoclonal 
IgG (red) and mouse anti-α-actin monoclonal IgG (green) respectively. F, Representative images of aortic root stained 
with Masson’s trichrome. G, mRNA expression levels of MCP-1, TNF-α, VCAM-1, α-actin, F4/80 and CD68 
normalised with GAPDH in aorta. *P < 0.05, **P < 0.01, ***P < 0.001. (n=9-12). 
100 μm 
200 μm 
100 μm
100 μm 
